Study of MCLA-158 for advanced solid tumors
Part of Cancer, Digestive system clinical trials.
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that has spread and standard treatments are no longer working.
- You are in fairly good physical shape (able to be up and about) and expected to live at least 12 weeks.
- You are willing to have a fresh tumor sample taken (biopsy) before starting the study.
- Your cancer is either head and neck cancer (after certain treatments) or colorectal cancer that meets specific genetic profiles.
- You have not had untreated or symptomatic brain metastases, and your heart, liver, and kidney function are adequate.
- You are not pregnant or breastfeeding and agree to use effective birth control during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This early-phase trial tests MCLA-129, an antibody that targets EGFR and MET, in people with advanced cancers that have specific lab “biomarker” results. It’s for patients whose cancer has grown after standard treatments or can’t take standard treatment, with the goal of shrinking tumors and improving symptoms.
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
This trial is testing a new combination of drugs (osemitamab, pembrolizumab, and chemotherapy) as the first treatment for advanced stomach cancer. It's for people whose tumors have a specific marker called Claudin 18.2, which might make the treatment more effective.
This study tests a new radioactive treatment for people with advanced solid tumors, such as certain lung, colon, head and neck, or bile duct cancers, that have stopped responding to standard treatments. The treatment targets a protein called c-MET found on cancer cells, aiming to deliver radiation directly to the tumor.
Hear when a new Advanced/Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.